Quanterix Corp (QTRX): auditor change — Quanterix restates prior financials for inventory errors; Q3 revenue $35.7M (+13% YoY)

Quanterix Corp

2024-Q3 EPS reported -$0.70 revenue$102,260,000

Revenue $35.7M (+13% YoY); GAAP gross margin 58.9%; reaffirms FY2024 revenue guidance $134-138M.
Restating financials for 2021-2024 due to inventory capitalization errors; non-reliance on prior statements.
Estimated restatement impacts: 2023 gross profit +$2.1M, operating loss -$2.3M; no material impact on cash or revenue.
Material weaknesses in internal control over inventory valuation continue; remediation ongoing.
Launched LucentAD Complete multi-marker Alzheimer's test; Mt. Sinai deploying blood-based biomarkers using Quanterix assays.

item 2.02 item 4.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Quanterix Corp reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

the need to restate certain previously issued financial statements as further described in Item 4.02 below

View on SEC.gov

21 auditor changes filed in the last 30 days. Browse all auditor changes →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001503274-24-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.